Evidence map›Paper›PMID 29186515›Full record

ArticleInternational journal of epidemiology2018

Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study.

Jue-Sheng Ong, Liang-Dar Hwang, Gabriel Cuellar-Partida, Nicholas G Martin, Georgia Chenevix-Trench, Michael C J Quinn, Marilyn C Cornelis, Puya Gharahkhani, Penelope M Webb, Stuart MacGregor and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in International journal of epidemiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Coffee consumption and cancer risk: a Mendelian randomisation study.Clinical nutrition (Edinburgh, Scotland) · 2022
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Jue-Sheng OngGenetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Liang-Dar HwangGenetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Gabriel Cuellar-PartidaGenetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Nicholas G MartinGenetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Georgia Chenevix-TrenchGenetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Michael C J QuinnGenetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Marilyn C CornelisNorthwestern University Feinberg School of Medicine, Preventive Medicine, Chicago, IL, USA.
Puya GharahkhaniGenetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Penelope M WebbPopulation Health Department, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Stuart MacGregorGenetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Ovarian Cancer Association Consortium
QIMR Berghofer Medical Research Institute · AUUniversity of Queensland · AUNorthwestern University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Chang S Chan · 1997 to 2026
$94.5M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
Risk Factors for Breast Cancer in Younger NursesR01CA050385 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 1989 to 2019
$32.3M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
Northern California Cooperative Family Registry for Breast CancerU01CA069417 · NCI · NORTHERN CALIFORNIA CANCER CENTER · PI JOHN, ESTHER M. · 1995 to 2010
$22.4M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
RPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B. · 2013 to 2025
$19.6M
USC CANCER EPIDEMIOLOGY &BIOSTATISTICS UNITP01CA017054 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PIKE, MALCOLM C · 1985 to 2009
$18.2M
Life Course Cancer Epidemiology Cohort in WomenUM1CA176726 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2013 to 2017
$15.7M
Novel Serum, Plasma, and Urine Biomarkers of Ovarian CanP50CA105009 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 2004 to 2010
$13.3M
Cancer Research UK C490/A10119Cancer Research UK C490/A10124Cancer Research UK C490/A6187CIHR MOP-86727NCI NIH HHS K07 CA080668NCI NIH HHS K07 CA095666NCI NIH HHS K07 CA143047NCI NIH HHS K22 CA138563NCI NIH HHS N01 PC035137NCI NIH HHS N01 PC067010NCI NIH HHS P01 CA017054NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA072720NCI NIH HHS P50 CA105009NCI NIH HHS P50 CA136393NCI NIH HHS P50 CA159981NCI NIH HHS R01 CA049449NCI NIH HHS R01 CA050385NCI NIH HHS R01 CA054419NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA058860NCI NIH HHS R01 CA063678NCI NIH HHS R01 CA063682NCI NIH HHS R01 CA067262NCI NIH HHS R01 CA074850NCI NIH HHS R01 CA083918NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA095023NCI NIH HHS R01 CA112523NCI NIH HHS R01 CA114343NCI NIH HHS R01 CA122443NCI NIH HHS R01 CA126841NCI NIH HHS R01 CA136924NCI NIH HHS R01 CA149429NCI NIH HHS R03 CA113148NCI NIH HHS R03 CA115195NCI NIH HHS U01 CA069417NCI NIH HHS U19 CA148112NCI NIH HHS UM1 CA176726NCI NIH HHS UM1 CA186107NCRR NIH HHS M01 RR000056
6 · The paper itself

Abstract

Background: Coffee consumption has been shown to be associated with various health outcomes in observational studies. However, evidence for its association with epithelial ovarian cancer (EOC) is inconsistent and it is unclear whether these associations are causal. Methods: We used single nucleotide polymorphisms associated with (i) coffee and (ii) caffeine consumption to perform Mendelian randomization (MR) on EOC risk. We conducted a two-sample MR using genetic data on 44 062 individuals of European ancestry from the Ovarian Cancer Association Consortium (OCAC), and combined instrumental variable estimates using a Wald-type ratio estimator. Results: For all EOC cases, the causal odds ratio (COR) for genetically predicted consumption of one additional cup of coffee per day was 0.92 [95% confidence interval (CI): 0.79, 1.06]. The COR was 0.90 (95% CI: 0.73, 1.10) for high-grade serous EOC. The COR for genetically predicted consumption of an additional 80 mg caffeine was 1.01 (95% CI: 0.92, 1.11) for all EOC cases and 0.90 (95% CI: 0.73, 1.10) for high-grade serous cases. Conclusions: We found no evidence indicative of a strong association between EOC risk and genetically predicted coffee or caffeine levels. However, our estimates were not statistically inconsistent with earlier observational studies and we were unable to rule out small protective associations.

Indexed as

Carcinoma, Ovarian EpithelialCoffeeFemaleHumansMendelian Randomization AnalysisOdds RatioOvarian NeoplasmsPolymorphism, Single NucleotideRisk FactorsCoffee

Identifiers

PMID29186515
PMCPMC6186013
OpenAlexW2772598231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.